EBS Stock — Emergent Biosolutions Inc

Emergent Biosolutions Inc (EBS)

Updated October 16, 2026.

EBS is a Stock. Total return is -38.7% over the past 19.9 years, 724.4 points behind SPY at 685.7%.

Emergent BioSolutions is a life sciences company that develops and manufactures medical countermeasures and emergency response products, including vaccines and therapeutics for threats like anthrax, smallpox, mpox, and botulism, along with opioid overdose reversal medications and contract manufacturing services. The company does not currently have an established distribution to shareholders. The stock may appeal to investors seeking exposure to the public health preparedness and biodefense sectors.

EBS performance versus SPY

Price and return data through 2026-10-16.

Total return is -38.7% over the past 19.9 years, 724.4 points behind SPY at 685.7%. Over the past year its total return — price change plus distributions reinvested — is -32.1%. Its deepest 1-year drawdown was 68.0%.

EBS key facts

Asset type

Stock

Asset class

Equity

Inception date

11/15/2006

Distribution frequency

None

Last close

$6.38 (as of 2026-10-16)

Market cap

$327,123,884

Average volume

2237072.0

Dividend

$1.855

Beta

2.337

Payout ratio

0.0%

Forward P/E

22.9885

EPS

$-3.41

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EBS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 68.0%.

Who may consider EBS — and who may not

It is a weaker fit for investors who need monthly cash flow (EBS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on EBS

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions